COVID-19 Advice for the JCU Community - Last updated: 27 September 2021, 10am (AEST)

QRC-PVD Clinical Trial - Fenofibrate in the Management of Abdominal Aortic Aneurysm (FAME)

This study aimed to test the effectiveness of a two-week course of a pharmaceutical, Fenofibrate, before surgery to repair Abdominal Aortic Aneurysms (AAA).

Recruitment status

Recruitment closed

Aneurysms slowly expand overtime at a rate of 2-4mm per year. The only treatment available is surgical intervention. No medications have been effective in slowing the growth rate of AAA. Previous studies found possible protective results in cholesterol-lowering medication like Fenofibrate.

Consenting participants attended our study centres a minimum of two times over four weeks. Forty-two participants enrolled in our study, which took place over six years.

The data collected from this study is still being analysed. Results will be published in peer-reviewed journal articles and communicated to participants.

See also:

Rowbotham, S.E., et al. (2017) Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial. Trials, 18:1 [doi:10.1186/s13063-016-1752-z]